ISSN 1662-4009 (online)

Previous issue | Volume 21 | ESPEYB21

Yearbook of Paediatric Endocrinology 2024

9. Oncology and Chronic Disease

Growth Problems in Cancer Survivors

ey0021.9-13 | Growth Problems in Cancer Survivors | ESPEYB21

9.13. GH and childhood-onset craniopharyngioma: when to initiate GH replacement therapy?

A Nguyen Quoc , K Beccaria , Briceno L Gonzalez , G Pinto , D Samara-Boustani , A Stoupa , J Beltrand , A Besancon , C Thalassinos , S Puget , T Blauwblomme , C Alapetite , S Bolle , F Doz , J Grill , C Dufour , F Bourdeaut , S Abbou , L Guerrini-Rousseau , A Leruste , S Brabant , I Cavadias , M Viaud , N Boddaert , M Polak , D Kariyawasam

Brief Summary: This retrospective, observational, single centre study compared the risk of tumor progression or recurrence in 71 patients with childhood-onset craniopharyngioma (CP) who started GH replacement therapy (GHRT) with different latency from the end of tumor treatment.GHRT latency was defined as the time from end of CP treatment (last debulking procedure or radiotherapy, or from CP diagnosis for the 5 patients without any debulking procedure or...

ey0021.9-14 | Growth Problems in Cancer Survivors | ESPEYB21

9.14. Exploring height outcomes with adjuvant aromatase inhibition in growth hormone-deficient male survivors of childhood cancer

NI Pollock , M Song , AJ Wolf , Y Li , CP Hawkes , N Motamedi , MR Denburg , S Mostoufi-Moab

Brief Summary: This single-center, retrospective cohort study compared the final adult height (FAH) of 92 male childhood cancer survivors (CCS) with growth hormone deficiency GHD) treated with growth hormone alone (monotherapy) or in combination with an aromatase inhibitor. The addition of AI to GH therapy did not improve FAH.This study from the Children’s Hospital of Philadelphia is the most extensive study on the role of AI associated with GH in i...

ey0021.9-15 | Growth Problems in Cancer Survivors | ESPEYB21

9.15. Association between conditioning intensity and height growth after allogeneic hematopoietic stem cell transplantation in children

S Uemura , D Hasegawa , K Kishimoto , T Fujikawa , S Nakamura , A Kozaki , A Saito , T Ishida , T Mori , K Ozaki , Y Kosaka

Brief Summary: This retrospective, single-center study from Kobe Children’s Hospital, Japan, analyzed height SDS (main outcome) and risk of short stature (height <-2 SDS, secondary outcome) in 89 children with malignant diseases who underwent initial allogenic hematopoietic stem cell transplantation (HSCT) with different conditioning intensities. More intensive conditioning conferred a substantially higher risk of short stature at 3 years after HSCT.<p class="abst...